NEW HAVEN, Conn.--CuraGen and Genentech announced that their drug research collaboration will continue for at least two-and-a-half-years. The deal, struck up in 1997, applies CuraGen's high-throughput functional genomic technologies and disease expertise to discovery of protein therapeutics and antibodies.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.